It came as a surprise, that delay of two and more chemotherapy courses insignificantly affected 5-year overall survival of women with HER2 positive tumour only, on the other hand it significantly affect survival of patients with ER-HER2- and ER + HER2- cancer subtypes. The gene discussed is ERBB2; the disease is neoplasm.